Salus Therapeutics Overview

  • Founded
  • 1999
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $14.1M
Latest Deal Amount

Salus Therapeutics General Information

Description

Developer of drugs based on deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). The company's drugs include antisense, small interfering RNAs and delivery systems for DNA/RNA-based drugs.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Acquirer
Genta
Primary Office
  • University Research Park
  • 615 Arapeen Drive, Suite 102
  • Salt Lake City, UT 84108
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Salus Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 21-Aug-2003 $14.1M 00.00 000.00 Completed Clinical Trials - Phase 2
4. Later Stage VC 01-Jun-2003 00000 00.00 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series B) 01-Jun-2002 00.00 00.00 Completed Generating Revenue
2. Early Stage VC (Series A) $1.2M Completed
1. Seed Round 01-Jul-1999 $1.2M Completed Startup
To view Salus Therapeutics’s complete valuation and funding history, request access »

Salus Therapeutics Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
EPIC Ventures Venture Capital Minority 000 0000 000000 0
Pelion Venture Partners Venture Capital Minority 000 0000 000000 0
Signal Peak Ventures Venture Capital Minority 000 0000 000000 0
To view Salus Therapeutics’s complete investors history, request access »